Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment

    October 2019 in “ Annals of palliative medicine ”
    Thomas McFarlane, Noor Rehman, Katie Wang … Caitlin Carter
    Studysummary This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on apm.amegroups.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Supportive Oncodermatology: Addressing Dermatologic Adverse Events Associated with Oncologic Therapies Oncology issues · 2018
    2. Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management DOAJ (DOAJ: Directory of Open Access Journals) · 2015
    3. Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies Annals of Oncology · 2015